Schäfer, Alexandra

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,615

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,488

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 1,041

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 900

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 675

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 613

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 532

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R. M., Gazumyan, A., Martinez, D. R., et al. (2021) · Journal of Experimental Medicine

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 305

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 185

Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes

Kapingidza, B., Marston, D. J., Harris, C., Wrapp, D., Winters, K., Mielke, D., Xiaozhi, L., Yin, Q., Foulger, A., Parks, R., et al. (2023) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 26

A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines

Lee, J., Stewart, C., Schäfer, A., Leaf, E. M., Park, Y.-J., Asarnow, D., Powers, J. M., Treichel, C., Sprouse, K. R., Corti, D., et al. (2024) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 23